Jonathan Moggs, Novartis Institutes for Biomedical Research, member of the SAB

Jonathan Moggs will talk about his work with drugs that modulate the epigenome in cancer and cell plasticity. By using small-molecule inhibitors of chromatin remodelers, his team aims to identify tumor dependencies on epigenetic regulators as well as developing new inhibitors for the treatment of BRG1-mutant lung cancers. Additionally, Jonathan’s team has been identifying chromatin-based disease modulators and testing BET inhibitors in regulation of keratinocyte plasticity. Finally, Jonathan will talk about translational safety assessment of epigenetic modulatory drugs.